Business Overview: ALX Oncology Holdings Inc. (Nasdaq: ALXO)

---

Executive Summary

ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company developing next-generation immuno-oncology therapies that target CD47, a "don't eat me" signal that cancer cells exploit to evade destruction by the immune system's macrophages. The company's lead candidate, evorpacept (ALX148), is a CD47-blocking fusion protein designed to be combined with other cancer therapies (chemotherapy, targeted antibodies, and other immuno-oncology agents) to enhance tumor cell killing across multiple solid tumor and hematologic cancer types.

ALX Oncology has no approved products and generates no meaningful product revenue; it is funded through equity financing and strategic collaborations, most notably with large pharmaceutical partners for combination studies.

---

1. Core Business Model & How They Work

As a clinical-stage biotech, ALX Oncology's model centers on advancing evorpacept through combination clinical trials with established cancer therapies, seeking to prove that CD47 blockade meaningfully improves outcomes when layered onto existing standards of care:

[ CD47-Targeting Fusion Protein Design ] ➡️ [ Phase 1 Combination Safety Trials ] ➡️ [ Phase 2 Combination Efficacy Trials (Multiple Tumor Types) ] ➡️ [ Pivotal Phase 3 Trial(s) ] ➡️ [ FDA Approval / Partner Licensing ]

Key Operational Drivers

1. Combination-First Strategy: Unlike some CD47 programs pursued as monotherapy, ALX Oncology has designed evorpacept specifically to be paired with existing approved therapies (e.g., trastuzumab for HER2+ gastric cancer, chemotherapy regimens, checkpoint inhibitors), aiming for a differentiated safety profile that avoids the anemia toxicity that has hindered other CD47 antibodies.
2. Differentiated Molecule Design: Evorpacept is engineered without an active Fc-effector function issue seen in some competing CD47 antibodies, which the company argues reduces red blood cell-related toxicity (a key limitation of earlier CD47-targeting drugs).
3. Partnership-Funded Pipeline Expansion: ALX Oncology has entered collaboration and license agreements with larger pharmaceutical and biotech partners to co-develop evorpacept in specific combination regimens, providing non-dilutive funding and expanded clinical reach.
4. Multiple Shots on Goal: The company is pursuing evorpacept across several tumor types (gastric/GEJ cancer, head and neck cancer, myelodysplastic syndrome, and others), diversifying its probability of a successful pivotal readout.

---

2. Competitive Landscape

Key Competitors

• Gilead Sciences (Forty Seven / magrolimab): The most prominent rival CD47-targeting program, which faced a partial clinical hold and setbacks tied to safety signals, reshaping investor perception of the CD47 target class broadly.
• Other CD47/SIRPα-pathway programs: Companies such as I-Mab (lemzoparlimab), Trillium Therapeutics (acquired by Pfizer), and various academic/biotech programs targeting the same macrophage checkpoint pathway.
• Broader immuno-oncology competitors: Established checkpoint inhibitor franchises (Merck's Keytruda, Bristol Myers Squibb's Opdivo) represent both potential combination partners and, in some respects, competing capital/attention within oncology R&D budgets.

Dynamics

The CD47/macrophage checkpoint field has seen significant volatility, with Gilead's magrolimab program encountering serious setbacks that raised broader doubts about the target class's safety and efficacy. ALX Oncology has positioned evorpacept's differentiated molecular design (engineered to minimize anemia) as its answer to those class-wide concerns, making the company's clinical execution and safety data particularly important to its competitive credibility.

---

3. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Differentiated protein engineering specifically designed to avoid the anemia toxicity that has plagued competing CD47-targeting antibodies.
• Diversified pipeline across multiple tumor types and combination partners, reducing single-trial binary risk relative to a single-indication competitor.
• Partnership relationships that provide both funding and clinical/commercial validation from more resourced pharma partners.

Strategic Risks

1. Target Class Skepticism: High-profile setbacks in competing CD47 programs (notably Gilead's) have made investors and potentially regulators more cautious about the entire target class.
2. Binary Clinical/Regulatory Risk: As with all clinical-stage biotech, a failed pivotal trial in a key indication would be a major setback.
3. Capital Requirements: Continued trial funding requires ongoing access to equity capital markets or partner funding.
   • Mitigation: Existing collaboration agreements provide some non-dilutive funding and cost-sharing.
4. Competitive Combination Landscape: Success depends partly on the continued relevance and combinability of partner drugs (e.g., chemotherapy backbones, HER2-targeted agents) that ALX Oncology does not control.

---

4. Financial Overview

---

5. Summary Conclusion

ALX Oncology represents a differentiated, combination-first approach to a genuinely important but scientifically contested cancer immunotherapy target — CD47 — with a molecular design specifically engineered to sidestep the safety issues that have derailed rival programs.

The company's long-term prospects hinge on whether evorpacept can generate clean, statistically compelling efficacy and safety data across its combination trials, restoring broader confidence in CD47-targeted therapy as a viable addition to the immuno-oncology treatment arsenal, in a field where a well-funded rival's stumble has raised the bar of proof required.